BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 17,290,000 shares, a decline of 10.7% from the November 30th total of 19,360,000 shares. Based on an average trading volume of 1,990,000 shares, the short-interest ratio is presently 8.7 days.

BioCryst Pharmaceuticals Stock Down 0.1 %

Shares of BCRX traded down $0.01 on Wednesday, hitting $7.52. The company’s stock had a trading volume of 1,513,767 shares, compared to its average volume of 2,813,235. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -12.33 and a beta of 1.79. The firm’s fifty day moving average price is $7.63 and its 200-day moving average price is $7.49. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. The firm’s revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.19) EPS. As a group, equities analysts predict that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on BCRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Barclays boosted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $15.60.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its stake in BioCryst Pharmaceuticals by 12.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 775,957 shares of the biotechnology company’s stock valued at $4,795,000 after acquiring an additional 86,249 shares in the last quarter. Signaturefd LLC lifted its position in shares of BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares in the last quarter. nVerses Capital LLC acquired a new position in BioCryst Pharmaceuticals during the second quarter worth $63,000. Rhumbline Advisers grew its position in BioCryst Pharmaceuticals by 6.3% in the second quarter. Rhumbline Advisers now owns 318,665 shares of the biotechnology company’s stock valued at $1,969,000 after purchasing an additional 18,916 shares in the last quarter. Finally, TD Asset Management Inc acquired a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at $1,487,000. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.